The keyhole surgery equipment developer has had a mixed time since coming to AIM at the beginning of the year. Problems in its Haemocell blood products division led to turnover in the year to 31 December dropping from £1.67m to £1.26m, while reduced administration expenses and an increase in margins meant that the net loss was trimmed from £1.05m to £694,000. On the positive side, the company won a Gold Award for Excellence for its F4 range of hand-held minimally invasive surgery devices. A new division has also been set up to maximise the company's R&D expertise, and is expected to boost profitability in the current year.